View on Pubmed.gov 20835230 | View on doi.org 10.1038/ni.1935
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.
- Immunology Research Centre, School of Biochemistry and Immunology, Trinity College, Dublin, Ireland. smasters@tcd.ie
Abstract
Interleukin 1β (IL-1β) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1β. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1β production in vitro. Processing of IL-1β initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1β in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP.
References
Proc Natl Acad Sci U S A. 1987 Jun;84(11):3881-5
J Neurochem. 2000 Mar;74(3):1017-25
Diabetologia. 2009 Jan;52(1):145-53
ILAR J. 2006;47(3):225-33
Cited by 1240 citations (total)
Journal Article
The role of the NLRP3 inflammasome in gout.
Electronic publication date November 19, 2011
Sarah R Kingsbury [...] Michael F McDermott et al.
Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU)...
Journal Article Research Support, Non-U.S. Gov't
Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscle.
Electronic publication date June 7, 2011
Karim Bouzakri [...] Philippe A Halban et al.
OBJECTIVE
Type 2 diabetes is characterized by insulin resistance with a relative deficiency in insulin secretion. This study explored the potential...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •
- •